I’m giving a talk at Pittcon on biotechnology training this spring. As many readers know, I have been very active in biotechnology education through my books and the classes I teach. So, I’ve got a strong sense of the supply-side of biotechnology education and training, and the academic side of biotechnology education, but would like some more perspective on the industry side of biotechnology education and training.
So, I’d like to post an open question:
How do you train your new biotechnology employees?
I want to learn more about the training systems used to bring new hires, with either scientific or business backgrounds, up to speed on the business of biotechnology. What are the methods and tools you use? You may post your response in the comments below, or if you’d rather be off the record, feel free to contact me directly.
Moira Gunn’s Tech Nation interview of Jeremy Abbate and I on the Scientific American worldView project is now available at IT Conversations. For more details, you can also see our video interview and the worldView website.
I’m honored to have been selected as one of the judges of the 2010 Biotech Humanitarian award. More details are available in a press release and blog post about the award. The Biotechnology Industry Association created the Award to recognize an everyday hero who has helped to heal, fuel and feed the planet through their work in the broad biotech arena.
BIO is accepting nominations for the 2010 Award via www.iambiotech.org/award through January 31, 2010.
The January 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 16, Issue 1
|Why data exclusivity is the new patent protection||PDF|
|Peter J Pitts|
|Follow-on biologic drug competition – No need for new marketing exclusivities||PDF|
|Michael S Wroblewski, Elizabeth A Jex|
Legal and Regulatory Updates
Drug Patent Expirations in January 2010
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number|| Patent Expiration|
|XOPENEX||Sepracor||levalbuterol hydrochloride||6,083,993||Jan 5, 2010|
|XOPENEX HFA||Sepracor||levalbuterol tartrate||5,844,002||Jan 5, 2010|
|XOPENEX||Sepracor||levalbuterol hydrochloride||5,844,002||Jan 5, 2010|
|XOPENEX HFA||Sepracor||levalbuterol tartrate||5,760,090||Jan 5, 2010|
|XOPENEX HFA||Sepracor||levalbuterol tartrate||6,083,993||Jan 5, 2010|
|XOPENEX||Sepracor||levalbuterol hydrochloride||5,760,090||Jan 5, 2010|
|MONOPRIL||Bristol Myers Squibb||fosinopril sodium||5,006,344*PED||Jan 10, 2010|
|MONOPRIL-HCT||Bristol Myers Squibb||fosinopril sodium; hydrochlorothiazide||5,006,344*PED||Jan 10, 2010|
|CLARINEX||Schering||desloratadine||5,178,878||Jan 12, 2010|
|REMERON SOLTAB||Organon Usa Inc||mirtazapine||5,178,878||Jan 12, 2010|
|ORAPRED ODT||Sciele Pharma Inc||prednisolone sodium phosphate||5,178,878||Jan 12, 2010|
|FAZACLO ODT||Azur Pharma Intl||clozapine||5,178,878||Jan 12, 2010|
|ALLEGRA||Sanofi Aventis Us||fexofenadine hydrochloride||5,178,878||Jan 12, 2010|
|REFLUDAN||Bayer Hlthcare||lepirudin recombinant||5,180,668||Jan 19, 2010|
|ELMIRON||Ortho Mcneil Janssen||pentosan polysulfate sodium||5,180,715||Jan 19, 2010|
|VFEND||Pfizer||voriconazole||5,376,645||Jan 23, 2010|
|GEODON||Pfizer||ziprasidone mesylate||5,376,645||Jan 23, 2010|
|NEXTERONE||Prism Pharms||amiodarone hydrochloride||5,134,127||Jan 23, 2010|
|VFEND||Pfizer||voriconazole||5,134,127||Jan 23, 2010|
|GEODON||Pfizer||ziprasidone mesylate||5,134,127||Jan 23, 2010|
Courtesy of DrugPatentWatch.com
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.